Clinical Research Trials : Hepatitis

Hepatitis

ABI-H0731-211-A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients
o Classification: HBV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Diane Sabogal
o Contact: (305) 243-1501 / d.sabogal@med.miami.edu

GS-US-320-0108: A phase 3, randomized, double blind study to evaluate the safety and efficacy of tenofovir alafenamide (TAF) 25 mg QD versus Tenofovir disproxil fumarate (TDF) 300mg QD for the treatment of HBeAg-Negative, Chronic Hepatitis B
o Classification: HBV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Diane Sabogal
o Contact: (305) 243-1501 / d.sabogal@med.miami.edu

GS-US-320-0110: A phase 3, randomized double-blind study to evaluate the safety and efficacy of Tenofovir alafenamide (TAF) 25 mg QD versus Tenofovir disoproxil fumarate (TDF) 300 mg QD for the treatment of HBeAg Positive, chronic Hepatitis B
o Classification: HBV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Diane Sabogal
o Contact: (305) 243-1501 / d.sabogal@med.miami.edu

209668-Phase IIb Multi-Center, Randomized, Partial-Blind [Sponsor and Participant Blinded, Site Staff Unblinded] Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus
o Classification: HBV
o Status: Open enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Lourdes Onate
o Contact: (305) 243-6939 / malourdeso@med.miami.edu

ABI-H0731-205-A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors
o Classification: HBV
o Status: Open enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Diane Sabogal
o Contact: (305) 243-1501 / d.sabogal@med.miami.edu

ABI-H0731-201-A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection
o Classification: HBV
o Status: Open enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Diane Sabogal
o Contact: (305) 243-1501 / d.sabogal@med.miami.edu

Target HBV-An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection
o Classification: HBV
o Status: Open enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Katrina Munoz
o Contact: (305) 243-6500 / kxm759@med.miami.edu

GS-US-337-1431: A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials
o Classification: HCV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Lourdes Onate
o Contact: (305) 243-6939 / malourdeso@med.miami.edu

HCV-Target PCORITHE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-­‐Making for Patients, Providers, and Stakeholders.
o Classification: HCV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Katrina Munoz
o Contact: (305) 243-6500 / kxm759@med.miami.edu

HCVTARGET: Hepatitis C Therapeutic Registry and Research Network A Longitudinal, Observational Study
o Classification: HCV
o Status: Closed enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Olivia Blust
o Contact: (305) 243-2855 / oib5@med.miami.edu

EIG-LNF-011-A PHASE 3, MATRIX DESIGN, PARTIALLY DOUBLE-BLIND, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF 50 MG LONAFARNIB/ 100 MG RITONAVIR BID WITH AND WITHOUT 180 MCG PEG IFN-ALFA-2A FOR 48 WEEKS COMPARED WITH PEG IFN-ALFA-2A ONOTHERAPY AND PLACEBO TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HEPATITIS DELTA VIRUS BEING MAINTAINED ON ANTI-HBV NUCLEOSIDE THERAPY (D-LIVR)
o Classification: HepD
o Status: Open enrollment, Open
o PI: Dr. Eugene Schiff
o Coordinator: Edgar Medina
o Contact: (305) 243-0236 / ejm202@med.miami.edu